Effect of perampanel, a novel AMPA antagonist, on benzodiazepine-resistant status epilepticus in a lithium-pilocarpine rat model

Pharmacology Research and Perspectives

Volumn 2, Issue 5, 2014, Pages

  Hanada, Takahisa ^a,b   Ido, Katsutoshi ^a   Kosasa, Takashi ^a  

^a EISAI CO LTD   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

AMPA receptor antagonist; benzodiazepine resistant; diazepam; lithium pilocarpine; perampanel; status epilepticus

Indexed keywords

4 AMINOBUTYRIC ACID; AMPA RECEPTOR ANTAGONIST; BENZODIAZEPINE; DIAZEPAM; LITHIUM CHLORIDE; PENTOBARBITAL; PERAMPANEL; PILOCARPINE;

AMYGDALA; ANIMAL MODEL; ARTICLE; ELECTRODE IMPLANTATION; ELECTROENCEPHALOGRAPHY; EPILEPTIC STATE; IMPLANTATION; MALE; MORTALITY RATE; NONHUMAN; PRIORITY JOURNAL; RAT; RIGHTING REFLEX; SEIZURE; TEMPORAL LOBE EPILEPSY;

EID: 84937123222     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.63     Document Type: Article

References (33)

1. Borowicz KK, Luszczki J, Szadkowski M, Kleinrok Z, Czuczwar SJ (1999). Influence of LY 300164, an antagonist of AMPA/kainate receptors, on the anticonvulsant activity of clonazepam. Eur J Pharmacol 380: 67–72.
2. Borowicz KK, Kleinrok Z, Czuczwar SJ (2000). The AMPA/kainate receptor antagonist, LY 300164, increases the anticonvulsant effects of diazepam. Naunyn-Schmiedeberg's Arch Pharmacol 361: 629–635.
3. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. (2012). Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 17: 3–23.
4. Chen JW, Wasterlain CG (2006). Status epilepticus: pathophysiology and management in adults. Lancet Neurol 5: 246–256.
5. Chin RF, Neville BG, Scott RC (2004). A systematic review of the epidemiology of status epilepticus. Eur J Neurol 11: 800–810.
6. Deeb TZ, Maguire J, Moss SJ (2012). Possible alterations in GABAA receptor signaling that underlie benzodiazepine-resistant seizures. Epilepsia 53(Suppl. 9): 79–88.
7. European Medicines Agency (2012). Fycompa summary of product characteristics. Available at http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002434/WC500130815.pdf (accessed 26 March 2014).
8. Feng HJ, Mathews GC, Kao C, Macdonald RL (2008). Alterations of GABA A-receptor function and allosteric modulation during development of status epilepticus. J Neurophysiol 99: 1285–1293.
9. Food and Drug Administration (2012). Fycompa prescribing information. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202834lbl.pdf (accessed 26 March 2014).
10. Fritsch B, Stott JJ, Joelle Donofrio J, Rogawski MA (2010). Treatment of early and late kainic acid-induced status epilepticus with the noncompetitive AMPA receptor antagonist GYKI 52446. Epilepsia 51: 108–117.
11. Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, et al. (2011). Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52: 1331–1340.
12. Hocker SE, Britton JW, Mandrekar JN, Wijdicks EF, Rabinstein AA (2013). Predictors of outcome in refractory status epilepticus. JAMA Neurol 70: 72–77.
13. Hui AC, Joynt GM, Li H, Wong KS (2003). Status epilepticus in Hong Kong Chinese: aetiology, outcome and predictors of death and morbidity. Seizure 12: 478–482.
14. Jones DM, Esmaeil N, Maren S, Macdonald RL (2002). Characterization of pharmacoresistance to benzodiazepines in the rat Li-pilocarpine model of status epilepticus. Epilepsy Res 50: 301–312.
15. 2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci 17: 7532–7540.
16. Langer M, Brandt C, Zellinger C, Löscher W (2011). Therapeutic window of opportunity for the neuroprotective effect of valproate versus the competitive AMPA receptor antagonist NS1209 following status epilepticus in rats. Neuropharmacology 61: 1033–1047.
17. Martin BS, Kapur J (2008). A combination of ketamine and diazepam synergistically controls refractory status epilepticus induced by cholinergic stimulation. Epilepsia 49: 248–255.
18. Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. (2006). EFNS guideline on the management of status epilepticus. Eur J Neurol 13: 445–450.
19. Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. (2010). EFNS guideline on the management of status epilepticus in adults. Eur J Neurol 17: 348–355.
20. Morimoto K, Sato H, Yamamoto Y, Watanabe T, Suwaki H (1997). Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy. Epilepsia 38: 966–974.
21. Naylor DE (2010). Glutamate and GABA in the balance: convergent pathways sustain seizures during status epilepticus. Epilepsia 51(Suppl. 3): 106–109.
22. Naylor DE, Liu H, Wasterlain CG (2005). Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci 25: 7724–7733.
23. Novy J, Logroscino G, Rossetti AO (2010). Refractory status epilepticus: a prospective observational study. Epilepsia 51: 251–256.
24. Paxinos G, Watson C (2007). The rat brain in stereotaxic coordinates, 6th ed. Academic Press, London.
25. Pitkanen A, Mathiesen C, Ronn LC, Moller A, Nissinen J (2007). Effect of novel AMPA antagonist, NS1209, on status epilepticus. An experimental study in rat. Epilepsy Res 74: 45–54.
26. Racine RJ (1972). Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr Clin Neurophysiol 32: 281–294.
27. Rajasekaran K, Todorovic M, Kapur J (2012). Calcium-permeable AMPA receptors are expressed in a rodent model of status epilepticus. Ann Neurol 72: 91–102.
28. Rice AC, DeLorenzo RJ (1999). N-methyl-D-aspartate receptor activation regulates refractoriness of status epilepticus to diazepam. Neuroscience 93: 117–123.
29. Rogawski MA (2011). Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 11: 56–63.
30. Rossetti AO, Logroscino G, Bromfield EB (2005). Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 62: 1698–1702.
31. Shneker BF, Fountain NB (2003). Assessment of acute morbidity and mortality in nonconvulsive status epilepticus. Neurology 61: 1066–1073.
32. Sutter R, Marsch S, Fuhr P, Ruegg S (2013). Mortality and recovery from refractory status epilepticus in the intensive care unit: a 7-year observational study. Epilepsia 54: 502–511.
33. Walton NY, Treiman DM (1988). Response of status epilepticus induced by lithium and pilocarpine to treatment with diazepam. Exp Neurol 101: 267–275.